Purpose: e use of morning basal serum cortisol levels as an alternative to dynamic testing for assessment of hypothalamic-pituitary-adrenal (HPA) axis has previously been reported. e purpose of this study was to determine the lower and upper cuto values that would obviate subsequent HPA axis testing.
A variety of tests have been reported in the literature to assess the hypothalamic-pituitary-adrenal axis (HPA) insu ciency. Although the insulin tolerance test (ITT) is mostly regarded as the gold standard, the adrenocorticotropin (ACTH) stimulation test has been proposed as a reliable alternative to the more cumbersome ITT [1] [2] [3] [4] . Both the ITT and the ACTH test, generally regarded as 'dynamic tests' , require medical supervision and the ITT is contraindicated in patients with seizure disorders, arrhythmias and ischemic heart disease, which impedes the utility of these tests as simple, e ective screening tools. Studies have looked at the role of morning basal cortisol drawn between 0800-0900h as a screening test that typically re ects the highest physiologic levels attained throughout the day, usually peaking 30-45 minutes a er awakening [5] . ese studies have generally focused on speci c patient populations of pre- [6, 7] and post-pituitary surgeries [8, 9] and consequently proposed variable lower and upper serum basal cortisol levels that would obviate the need for patients to undergo further dynamic testing. [8, [10] [11] [12] [13] . e primary purpose of this study was twofold: a) to assess the association between morning basal serum cortisol and serum cortisol levels a er dynamic test using a standard dose (250 μg) ACTH stimulation test; and, b) to determine upper and lower cuto values of morning basal cortisol that would obviate the need for dynamic testing in an outpatient setting.
Methods
e ueen Elizabeth II Health Sciences Centre is the sole tertiary care centre providing adult endocrinology services in the province of Nova Scotia, Canada. For this study, data was retrospectively collected from all patients referred to the adult (aged 18 years and older) endocrinology department between January 1, 2008 and December 31, 2012. All patients had undergone morning basal serum cortisol assessment between 0800h-0900h and, if they were on glucocorticoid therapy (hydrocortisone), this was done a er holding the previous a ernoon's (in patients taking thrice daily dose) and evening's doses, ensuring at least 24 hours since the last dose. Based on our previous protocol, a morning basal serum cortisol value of< 100 nmol/ was regarded as diagnostic of HPA insu ciency, a value of>300 nmol/L was regarded as normal, whereas those with morning basal serum cortisol values between 100-300 nmol/L underwent the 250µg ACTH stimulation test stimulation test and a peak (30-and/or 60-minute) serum cortisol value of >550nmol/L being regarded as a 'pass' based on previously published data [1, 14] . All but 10 patients had no history of exogenous glucocorticoid therapy within the past 8 weeks, whereas the 10 patients were on glucocorticoid weaning therapy with hydrocortisone (< 10 mg/m 2 /day). None of the patients had undergone an ACTH stimulation test within 12 weeks a er pituitary surgery. In addition, the data on the function of hypothalamic-pituitary-thyroid (HPT) and the hypothalamic-pituitary-gonadal (HPG) axes at the time of initial presentation were also collected to assess the impact of these axes on the HPA assessment. Secondary hypothyroidism (SHT) was de ned as a low serum free thyroxine (FT4) with either subnormal or inappropriately normal thyroid stimulating hormone (TSH), whereas secondary hypogonadism (SHG) was de ned as a low morning serum total testosterone/ estradiol with subnormal or inappropriately normal luteinizing (LH) and follicle stimulating hormones (FSH). Please refer to Appendix A for the reference ranges of our laboratory values.
e Capital Health Research Ethics Board approved the study. Serum cortisol, TSH, T4, LH, FSH, testosterone and estradiol were measured by radioimmunoassay, using Advia Centaur XP, Siemens Canada Limited, Mississauga, Ontario, Canada. e data were analyzed using "R project" version 2.14.2. Morning basal cortisol levels were used to predict the peak post-ACTH 30 or 60 minute values as >500 nmol/L or >550 nmol/L using Receiver Operator Curves (ROC). One hundred percent sensitivity/speci city rates (the points at which a basal cortisol cuto correctly classi ed all of the normal/ abnormal peak post-ACTH values, respectively) for>500 and>550 nmol/L, as well as the optimal morning serum cortisol cuto value were determined using the phi coe cient [15] . Simple and multiple linear regressions were performed to analyze the relationship between morning basal and peak serum cortisol levels, while controlling for the HPT and HPG values. For the regression, the peak cortisol values were logtransformed to account for non-normality.
Results
Patients ese data are summarized in Table 1 . A total of 106 individuals (66 females and 40 males) were studied. e median age was 48 years and the range was 26-87 years. e primary diagnoses are listed in Table 1 . Of all individuals, 18 patients had combined SHT and SHG, ve had isolated SHT and six had isolated SHG. e diagnoses of SHT and SHG were made in all patients at the time of original presentation and all patients had been on stable, adequate replacement therapy with sex hormones and levothyroxine for at least 3 months at the time of ACTH testing.
ere were 28/106 patients who had previously undergone pituitary resection. 
Morning basal serum cortisol vs. 250 μg ACTH test
e correlation between morning basal and peak serum cortisol was 0.52 and a log-transformation of the morning basal cortisol levels ( Figure 1 ) indicated a log-linear relationship between morning basal and peak cortisol values. e ROC analysis ( Figure 2 ) to assess the need for dynamic testing yielded slightly di erent morning basal cortisol values for peak post-ACTH values of>500 nmol/L or >550 nmol/L, as demonstrated in Table 2 .
e timing of peak cortisol, either 30 or 60 minutes post-ACTH, did not alter the ROC analysis signicantly (data not shown). Using two di erent outcome levels of peak post-ACTH values (>500 nmol/L and >550 nmol/L), three potential cuto levels for morning serum cortisol levels were determined: the point that ensured all cases of normal post-ACTH were identi ed (100% sensitivity), the point that ensured all cases of abnormal post-ACTH were identi ed (100% speci city) and the optimal cuto point, i.e., the cuto point that ensured the most correct classi cations.
In terms of morning basal cortisol vs. peak post-ACTH test, the peak value of > 550 nmol/L generated more robust cuto values as compared with that of >500 nmol/L (see Table  2 ). While using the peak post-ACTH level >500 nmol/L, the lower cuto for morning basal cortisol levels, which gave 100% speci city, was 52 nmol/L but only a few patients had basal levels below that point.
e upper cuto of 243 nmol/L was signi cantly more robust because all 17 patients with morning serum cortisol levels above that point had peak-ACTH levels above 500 nmol/L. For peak post-ACTH levels >550 nmol/L, the lower cuto was more de nitive because all 12 patients with morning serum cortisol levels below 128 nmol/L had peak levels below 550 nmol/L, and all 12 patients with morning serum cortisol levels above 266 nmol/L had peak levels above 550 nmol/L. Figure 1 presents these cuto levels and the > 550 nmol/L line, demonstrating their predictive power.
e regression analysis con rmed our ndings above, revealing the log-linear relationship demonstrated in Figure 1 .
e regression was signi cant (p<0.0001), indicating that morning serum cortisol levels are a signi cant predictor of peak post-ACTH levels.
Risk of HPA insu ciency in patients with other pituitary hormone de ciencies
SHT and SHG had a signi cant e ect on the post-ACTH levels, with SHT corresponding to a 77 nmol/L drop in peak Fatigue (16) glucocorticoid withdrawal (10) Pituitary tumour + radiation therapy (4) Non -pituitary sellar growth (6) Non-pituitary sellar growth + radiation therapy (6) Idiopathic pituitary insu ciency (5) Hypotension (2) Vomiting (1) Cranial radiation (1) ere was no correlation between either condition and morning serum cortisol levels.
e presence of additional pituitary insu ciencies increased the risk of HPA insu ciency. Odds ratios (OR) were calculated using the peak post-ACTH 30 or 60 minute cortisol value of >500 nmol/L. In patients with isolated SHT the OR of HPA insu ciency was 3.41 (p = 0.015), with isolated SHG was 4.77 (p = 0.002) and with combined SHT and SHG was 7.45 (p = 0.0002). Primary diagnosis including presence or absence of surgery did not have any e ect on the association between morning basal cortisol and peak ACTH test.
Discussion
Previous studies have surmised that serum basal cortisol can be used e ectively for predicting the integrity of the HPA axis in adults with reported lower cuto values as 80 -110 nmol/L and upper cuto values as 250 -494 nmol/L [8, [10] [11] [12] [13] . e lack of uniformity in these cuto levels could in part be attributed to di erences in study populations, variability of dynamic tests, di erent serum cortisol assays used, the cuto of peak serum cortisol that was deemed indicative of a normal HPA axis response, and the clinical context in which the studies were done.
A diverse group of patients was chosen for this study to provide a wider clinical context. A recent meta-analysis of 13 studies suggested that in ambulatory patients with no acute illness, but with suspected HP disorder, the cuto value below 138 nmol/ L best predicted HPA insu ciency in adults whereas an upper cuto value of 365 nmol/L excluded HPA insu ciency [16] . As expected, our data showed that morning basal cortisol cuto levels are dependent upon the peak post-ACTH value. is is an important issue as both values are reported in the literature and additional studies are required to further elucidate these di erences. In our study, the lower and upper cuto for morning basal cortisol against peak post-ACTH value of >500 nmol/L were 52 nmol/L and 243 nmol/L, respectively. Although this lower cuto of 52 nmol/L is signi cantly lower than previous studies (80-138 nmol/L), it is less robust because only two of the 106 patients met this, whereas the upper cuto of 243 nmol/L is more in keeping with the previously reported value of 250 nmol/L by Watts and Tindall [8] , but signi cantly lower than the recent meta-analysis cuto of 365 nmol/L [16] . On the other hand, if a peak cortisol level cuto of >550 nmol/L was used, the lower and upper morning serum cortisol levels were 128 nmol/L and 266 nmol/L, respectively. e lower cuto of 128 nmol/L is in line with the published data while the upper cuto of 266 nmol/L is again markedly lower than the one reported in the meta-analysis [16] . e standard dose ACTH stimulation test was used exclusively in this study as previous studies have established it as an e ective alternative to the more cumbersome ITT [3, 4] . ere are some limitations to the 250 μg ACTH stimulation test, particularly that it is less reliable in the rst two months postpituitary surgery [18] ; however, in our population, none of the ACTH stimulation tests was done within twelve weeks of pituitary surgery. Of note, Watts and Tindall also used the standard dose ACTH stimulation test 5-7 days and 1 month a er pituitary surgery [8] , which may explain why their reported values are closer to ours. It has also been suggested that, the timing of the peak cortisol, i.e., 30 or 60 minutes a er ACTH injection, may lead to diagnostic variability and consequently may have an impact on basal serum cortisol cuto levels [14, 17] ; however, our data did not show a statistically signicant e ect of either 30 or 60 minutes post ACTH value on the ROC analysis for both the 500 or 550 nmol/L peak cortisol cuto levels.
e standard 250 μg ACTH test, as opposed to the 'low dose' 1 μg ACTH, test was used exclusively in this study. Several studies have reviewed these tests reporting con icting results with some suggesting the the 1 μg ACTH stimulation test is superior [16] while others showing them to be equivalent [19] . Future studies will need to be done to evaluate if the low dose ACTH stimulation test is a better predictor.
Although most studies have been conducted in a perioperative setting, in this study a diverse outpatient population was analysed, making it more clinically relevant to most outpatient settings.
Our data reveals a novel nding that suggests that the presence of additional pituitary hormone de ciencies increases the risk of HPA de ciency. Although in this retrospective study, data regarding growth hormone de ciency was not available, the risk of HPA de ciency was assessed in patients with SHT, SHG or both. In patients who had originally presented with SHT, the risk of HPA insu ciency was 44%, with SHG it was 50% and with both SHT and SHG it was 61%. It is also noteworthy that all patients were well established on stable replacement therapy at the time when these data were collected. Larger studies should be conducted to assess the adequate morning basal serum cortisol values that may provide the appropriate diagnostic assessment of HPA axis in patients with multiple pituitary insu ciencies. Until this is clari ed, patients known to have at least one other known pituitary hormone de ciency should be regarded as having a high risk of HPA insu ciency.
Conclusion
In conclusion, our study further con rms the utility of morning basal cortisol as an e ective screening test for HPA insuciency. e appropriate morning basal cortisol values depend upon the cuto values used for the ACTH stimulation test. Furthermore, the risk of HPA insu ciency is signi cantly higher in patients with additional pituitary insu ciencies, thus suggesting that a high index of vigilance should be maintained in such cases. Patients with known pituitary hormone de ciencies should undergo early dynamic HPA axis testing. Our data also suggest the need for larger prospective studies to con rm this association and assess the adequate morning basal cortisol values in individuals with one or more pituitary insu ciencies.
